NCT05677464 (PRETTi) is a clinical trial in Obesity, sponsored by Endo Tools Therapeutics S.A..

Who is sponsoring NCT05677464?

NCT05677464 is sponsored by Endo Tools Therapeutics S.A..

Is NCT05677464 still recruiting?

NCT05677464 is currently status unknown. Last updated 10 January 2023.

Last reviewed 2023-01-10 · How we verify

NCT05677464: PRETTi

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Prospective Multicenter Study With the Endomina® Triangulation Platform

Status unknown Last updated 10 January 2023

What this trial tests

trial in Obesity in 1,000 participants. Status unknown.

Timeline

8 June 2020

Primary endpoint
31 March 2023

31 March 2026

Quick facts

Lead sponsor	Endo Tools Therapeutics S.A.
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	1,000
Start date	8 June 2020
Primary completion	31 March 2023
Estimated completion	31 March 2026
Sites	1 location across Belgium

Conditions studied

Obesity — all drugs for Obesity →

Sponsor

Endo Tools Therapeutics S.A.

Who can join

Adults 18 to 65, any sex, with Obesity. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This registry is designed to further assess on a larger scale safety and efficacy of the endomina® device and tissue apposition accessories (TAPES) when used in the frame of "real life" routine clinical practice

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Obesity

Currently open trials in the same condition.

NCT07403604 — Effect of Insulin Lowering on Lipogenesis · Phase 1 · recruiting
NCT07509307 — AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee · Phase 3 · recruiting
NCT07272837 — Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass · recruiting
NCT07481630 — A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoart · Phase 3 · recruiting
NCT07527195 — Understanding the Effect of CagriSema, Cagrilintide, and Semaglutide on Muscle Health (Role of Amylin Signature in Muscl · Phase 1 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05677464 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Endo Tools Therapeutics S.A.
Last refreshed: 10 January 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05677464.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing